U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C24H33N3O4
Molecular Weight 427.5365
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 1
Charge 0

SHOW SMILES / InChI
Structure of IVALTINOSTAT

SMILES

CN(C)CCCNC(=O)C(\COC1=C2C=CC=CC2=CC=C1)=C\CCCCC(=O)NO

InChI

InChIKey=AUGCSOFQTDKPSO-RGVLZGJSSA-N
InChI=1S/C24H33N3O4/c1-27(2)17-9-16-25-24(29)20(11-4-3-5-15-23(28)26-30)18-31-22-14-8-12-19-10-6-7-13-21(19)22/h6-8,10-14,30H,3-5,9,15-18H2,1-2H3,(H,25,29)(H,26,28)/b20-11+

HIDE SMILES / InChI

Molecular Formula C24H33N3O4
Molecular Weight 427.5365
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 1
Optical Activity NONE

CG-200745 is a novel inhibitor of histone deacetylases (HDACs), initially developed by CrystalGenomics, Inc for treatment of various hematological and solid cancers. Combinations of CG-200745 with SN38 (the active form of irinotecan), or oxaliplatin were more effective than the agents alone when used to inhibit the growth of HCT116 cells. The protein expressions of acetyl-H3, p21, caspase-3, -8, and -9, PARP, and XIAP were affected in a time- and dose-dependent manner in HCT116 cells treated with the CG-200745 alone or combined CG-200745 and SN-38. In HCT116 xenografts, the HDACI CG-200745 in combination with irinotecan dramatically inhibited tumor growth without showing additive toxicity.

Approval Year

PubMed

PubMed

TitleDatePubMed
Patents

Patents

Sample Use Guides

mice 30 mg/kg, 5 days/week
Route of Administration: Oral
Substance Class Chemical
Created
by admin
on Sat Dec 16 11:09:17 GMT 2023
Edited
by admin
on Sat Dec 16 11:09:17 GMT 2023
Record UNII
4I8MLM7L2H
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
IVALTINOSTAT
INN  
Official Name English
CG-200745
Preferred Name English
CG 2 (HDAC INHIBITOR)
Code English
CG-2
Code English
ivaltinostat [INN]
Common Name English
CG200745
Code English
HDCG-0745
Code English
2-OCTENEDIAMIDE, N1-(3-(DIMETHYLAMINO)PROPYL)-N8-HYDROXY-2-((1-NAPHTHALENYLOXY)METHYL)-, (2E)-
Systematic Name English
J3.106.463E
Code English
(E)-N-(3-(DIMETHYLAMINO)PROPYL)-N'-HYDROXY-2-((1-NAPHTHYLOXY)METHYL)-2-OCTENEDIAMIDE
Systematic Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 919022
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
FDA ORPHAN DRUG 760420
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
FDA ORPHAN DRUG 846121
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
FDA ORPHAN DRUG 793520
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID801028069
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY
SMS_ID
300000010881
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY
PUBCHEM
16117309
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY
CAS
936221-33-9
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY
MANUFACTURER PRODUCT INFORMATION
CG-200745
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY Description: CG200745 is a novel hydroxamate-based pan-histone deacetylase inhibitor (HDACI). Like other inhibitors, CG200745 has the hydroxamic acid moiety to bind zinc at the bottom of catalytic pocket. CG200745 inhibited deacetylation of histone H3 and tubulin as much as vorinostat and belinostat did. CG200745 also inhibited growth of prostate cancer cells, increased sub-G1 population, and activated caspase-9, -3 and -8 in LNCaP, DU145 and PC3 cells. These results indicate that CG200745 induces apoptosis. The preclinical results show that combination treatment with docetaxel and new HDACI, CG200745, potentiated anti-tumor effect in hormone-refractory prostate cancer (HRPC) cells via activation of apoptosis. (Last update: 5/30/2016).
CLINICAL_TRIALS.GOV
HDCG-0745
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY Official Title: A Phase I/II Study of Combination Therapy of CG200745 PPA With Gemcitabine and Erlotinib to Determine the Maximum Tolerated Dose (MTD) and Evaluate the Safety and Efficacy for Locally Advanced Unresectable, or Metastatic Pancreatic Cancer.The phase I clinical trial is to identify the MTD (Maximum Tolerated Dose) and DLT (Dose Limiting Toxicity) of CG200745 PPA in combination use of Gemcitabine and Erlotinib. Initial dose of CG200745 PPA is 187.5 mg/m^2, and it will be extended to 250 mg/m^2, 312.5 mg/m^2 or it will be reduced to 125 mg/m^2 based on the results of the cohort of 3 subjects per dose level.In the phase II clinical trial, the subjects will be administered with the dose which is to be identified as a recommended dose based on the results of Phase I study. The whole one cycle is consisted of 28 days, same as the phase I. The entire treatment period is 6 cycles and tumor assessment is evaluated every 2 cycles.
DRUG BANK
DB12259
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY
INN
11072
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY
CLINICAL_TRIALS.GOV
CG-200745
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY Official Title: A Phase I/II Study of CG200745 PPA to Determine the Maximum Tolerated Dose and Evaluate the Safety and Efficacy in Patients With Myelodysplastic Syndrome (MDS) Who Failed to Respond to Prior Hypomethylating Therapy
NCI_THESAURUS
C94225
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY
FDA UNII
4I8MLM7L2H
Created by admin on Sat Dec 16 11:09:17 GMT 2023 , Edited by admin on Sat Dec 16 11:09:17 GMT 2023
PRIMARY
Related Record Type Details
TARGET -> INHIBITOR
SALT/SOLVATE -> PARENT
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
TARGET -> INHIBITOR
Related Record Type Details
ACTIVE MOIETY
Originator: CrystalGenomics; Class: Antineoplastic; Mechanism of Action: Histone deacetylase inhibitor; Highest Development Phases: Phase II for Cancer, Phase I/II for Pancreatic cancer; Most Recent Events: 08 Apr 2016 CrystalGenomics plans a phase I/II trial for Myelodysplastic syndrome (Second-line therapy or greater) in South Korea (IV) (NCT02737462), 01 Mar 2016 Phase-I/II clinical trials in Pancreatic cancer (Metastatic disease, Combination therapy, Inoperable/Unresectable, Late-stage disease, First-line therapy) in South Korea (IV) (NCT02737228), 11 Feb 2016 Phase-II development is ongoing in South Korea